Planning for a global product launch means a coherent evidence plan and value dossier must address the needs of multiple geographies. This session will review the evolving perspectives of US payers on evidence for medical devices, and contrast these trends with major EU markets and Japan. Specific topics to be addressed will include:
Principal and Founder
Hull Associates, USA
This is the presenters’ personal opinion and does not necessarily represent true facts, the official views or policy of their organisation, nor the views of NextLevel Life Sciences.